5.04314
硼替佐米
≥98% (LC/MS), solid, 20S proteasome inhibitor, Calbiochem®
别名:
硼替佐米, (R)-3-甲基-1-((S)-3-苯基-2-(吡嗪-2-羧酰胺基)丙酰胺基)丁基硼酸，BTZ，LDP-341，LDP341，MG341，MLN-341，MLN341，PS341，蛋白酶体抑制剂XXII，PS-341，MG-341，Pyz-Phe-boroLeu
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H25BN4O4
化学文摘社编号:
分子量:
384.24
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (LC/MS)
Form:
solid
Quality level:
Storage condition:
OK to freeze
desiccated (hygroscopic)
protect from light
desiccated (hygroscopic)
protect from light
产品名称
硼替佐米,
SMILES string
B(O)(O)[C@@H](NC(=O)[C@@H](NC(=O)c2nccnc2)Cc1ccccc1)CC(C)C
InChI
1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChI key
GXJABQQUPOEUTA-RDJZCZTQSA-N
assay
≥98% (LC/MS)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
color
off-white
solubility
DMSO: 100 mg/mL
ethanol: 2 mg/mL (with sonication)
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
硼替佐米已用于诱发小鼠的有氧糖酵解/神经病理性疼痛，研究化疗所致痛性周围神经病变。
Biochem/physiol Actions
可逆性：是
细胞可渗透性：具有
Disclaimer
毒性：标准处理（A）
Features and Benefits
- 细胞可渗透，可靶向作用
- 可逆调节细胞过程
General description
硼替佐米是一种细胞渗透性的二肽基硼酸酯化合物，用作蛋白酶体抑制剂。蛋白酶体系统在细胞蛋白周转中发挥重要作用，对于细胞稳态维持至关重要。硼替佐米可逆结合26S蛋白酶体的胰凝乳蛋白酶样亚基抑制其功能，从而抑制多个促凋亡因子的降解。硼替佐米选择性抑制20S蛋白酶体β5 ChTL/胰凝乳蛋白酶样活性、β1 Cl/胱天蛋白酶样活性和β2 TL/胰蛋白酶样活性（各自的kinact/Ki = 38,000、5,700、<100 M-1s-1，人体20S蛋白酶体检测使用10 M Suc-LLVY-AMC/货号539142，10M Z-LLE-AMC/货号539141，或50M Boc-LRR-AMC作为底物；1小时内各自IC50 = 7, 74和4,200 nM），通过催化β亚基的亲核Thr1羟基/Thr10γ与抑制剂亲电子硼部分之间以一种共价、缓慢可逆方式相互作用而进行抑制，对人胰凝乳蛋白酶、组织蛋白酶G、白细胞弹性蛋白酶和凝血酶展现出的效力大大降低（各自Ki = 0.32, 0.63, 2.3和13 M，对比使用620 nM兔肌肉20S）。一种在体外培养和动物体内中广泛使用的抑制剂。尽管是首个被FDA批准用于临床抗癌治疗的蛋白酶体抑制剂，它的治疗功效仍然受到了脱靶作用和剂量限制性毒性的影响。
Other Notes
Du, X.L, and Chen, Q. 2013.Acta Haematol.129, 207.
Tamatani, T., et al. 2013.Int. J. Oncol.42, 935.
Beck, P., et al. 2012.J. Biol. Chem.393, 1101.
Fang, H.T., et al. 2012.Proc.Natl.Acad.Sci. USA.109, 2521.
Chen, D., et al. 2011.Curr.Cancer Drug Targets11, 239.
Demo, S.D., et al. 2007.Cancer Res.67, 6383.
Adams, J., et al. 1999.Cancer Res.59, 2615.
Teicher, B.A., et al. 1999.Cancer Res.5, 2638.
Adams, J., et al. 1998.Bioorg.Med. Chem. Lett.8, 333.
Tamatani, T., et al. 2013.Int. J. Oncol.42, 935.
Beck, P., et al. 2012.J. Biol. Chem.393, 1101.
Fang, H.T., et al. 2012.Proc.Natl.Acad.Sci. USA.109, 2521.
Chen, D., et al. 2011.Curr.Cancer Drug Targets11, 239.
Demo, S.D., et al. 2007.Cancer Res.67, 6383.
Adams, J., et al. 1999.Cancer Res.59, 2615.
Teicher, B.A., et al. 1999.Cancer Res.5, 2638.
Adams, J., et al. 1998.Bioorg.Med. Chem. Lett.8, 333.
Packaging
用惰性气体包装
Preparation Note
仅使用新鲜的DMSO或乙醇用于重悬。
在重悬后分装并冻存于冰箱（-20°C.）储备溶液在-20°C下可稳定保存至多6个月。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Panjamurthy Kuppusamy et al.
Frontiers in pain research (Lausanne, Switzerland), 5, 1424348-1424348 (2024-07-09)
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment that significantly impacts patients' quality of life. This study investigated the effects of targeting metabolic pathways on bortezomib-induced neuropathic pain and tumor growth using a Lewis lung carcinoma
Susan D Demo et al.
Cancer research, 67(13), 6383-6391 (2007-07-10)
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. Here we describe the antitumor activity of PR-171, a
J Adams et al.
Bioorganic & medicinal chemistry letters, 8(4), 333-338 (1999-01-01)
Potent and selective dipeptidyl boronic acid proteasome inhibitors are described. As compared to peptidyl aldehyde compounds, boronic acids in this series display dramatically enhanced potency. Compounds such as 15 are promising new therapeutics for treatment of cancer and inflammatory diseases.
B A Teicher et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 5(9), 2638-2645 (1999-09-28)
The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examined in vitro and in vivo. PS-341 was a potent cytotoxic agent toward MCF-7 human breast carcinoma cells in culture, producing an IC90 of 0.05 microM on 24
D Chen et al.
Current cancer drug targets, 11(3), 239-253 (2011-01-21)
Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib was subsequently approved for the clinical use as a front-line treatment for newly diagnosed multiple myeloma
相关内容
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持